Enhua Pharmaceutical (002262.SZ) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Zhitong Finance App News, Enhua Pharmaceutical (002262.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for the Class 1 chemical NH103 oxalate tablets approved and issued by the State Drug Administration and agreed to carry out clinical research on antidepressants.
NH103 has strong and balanced inhibitory activity against serotonin transporter (SERT), a commonly used antidepressant target, and 5HT2A/5HT2C receptors, a target that enhances antidepressant activity. The mechanism of action is unique. Currently, no antidepressants with the same mechanism are on the market. At the same time, NH103 also has the advantages of low risk of dependency, sleep aid, and few residual symptoms (preclinical toxicology and safety pharmacology studies have not found adverse effects affecting social function, such as weight gain, drowsiness, or decreased blood pressure), and has high clinical value and benefits. For the above drugs, the company will conduct clinical trials in accordance with the requirements of the “Drug Clinical Trial Approval Notice” issued by the Drug Administration. If the above drugs are successfully developed and marketed in the future, it will further enrich the company's central nervous system product line.